BenevolentAI SA is a holding company, which engages in the research and development and sale of AI-enabled drugs. Its business platform combines artificial intelligence and machine learning in discovering medicines. It operates through the UK and Europe geographical segments. The company was founded by Ivan Griffin, Kenneth Patrick Mulvany, and Michael Brennan in November 2013 and is headquartered in London, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company